RS59207B1 - Formulacije anti-prolaktin receptorskog antitela - Google Patents

Formulacije anti-prolaktin receptorskog antitela

Info

Publication number
RS59207B1
RS59207B1 RSP20190823A RS59207B1 RS 59207 B1 RS59207 B1 RS 59207B1 RS P20190823 A RSP20190823 A RS P20190823A RS 59207 B1 RS59207 B1 RS 59207B1
Authority
RS
Serbia
Prior art keywords
receptor antibody
antibody formulations
prolactin receptor
prolactin
formulations
Prior art date
Application number
Other languages
English (en)
Inventor
Xinghang Ma
Jun Xiang
Jianjie Niu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of RS59207B1 publication Critical patent/RS59207B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RSP20190823 2012-08-31 2013-08-28 Formulacije anti-prolaktin receptorskog antitela RS59207B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261695949P 2012-08-31 2012-08-31
US13/842,906 US8883979B2 (en) 2012-08-31 2013-03-15 Anti-prolactin receptor antibody formulations
PCT/US2013/056976 WO2014036076A1 (en) 2012-08-31 2013-08-28 Anti-prolactin receptor antibody formulations
EP13760180.3A EP2890397B1 (en) 2012-08-31 2013-08-28 Anti-prolactin receptor antibody formulations

Publications (1)

Publication Number Publication Date
RS59207B1 true RS59207B1 (sr) 2019-10-31

Family

ID=49162240

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP20190823 RS59207B1 (sr) 2012-08-31 2013-08-28 Formulacije anti-prolaktin receptorskog antitela

Country Status (30)

Country Link
US (4) US8883979B2 (sr)
EP (1) EP2890397B1 (sr)
JP (1) JP6444871B2 (sr)
KR (1) KR102100282B1 (sr)
CN (3) CN111202843A (sr)
AR (2) AR092387A1 (sr)
AU (1) AU2013308907B2 (sr)
BR (1) BR112015004397B1 (sr)
CA (1) CA2883097C (sr)
CY (1) CY1121990T1 (sr)
DK (1) DK2890397T3 (sr)
ES (1) ES2742868T3 (sr)
HK (1) HK1207316A1 (sr)
HR (1) HRP20191199T1 (sr)
HU (1) HUE045494T2 (sr)
IL (1) IL237277B (sr)
IN (1) IN2015DN02255A (sr)
LT (1) LT2890397T (sr)
MX (1) MX367691B (sr)
NZ (1) NZ705178A (sr)
PL (1) PL2890397T3 (sr)
PT (1) PT2890397T (sr)
RS (1) RS59207B1 (sr)
RU (1) RU2649372C2 (sr)
SG (1) SG11201501225SA (sr)
SI (1) SI2890397T1 (sr)
TW (3) TW201422235A (sr)
UY (2) UY34994A (sr)
WO (1) WO2014036076A1 (sr)
ZA (1) ZA201501279B (sr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2825553T3 (en) 2012-03-14 2018-09-24 Regeneron Pharma : Multispecific antigen binding molecules and applications thereof
SI2935331T1 (en) 2012-12-24 2018-06-29 Abbvie Inc. Protein that binds the prolactin receptor and its use
US20160002342A1 (en) * 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AU2016218074B2 (en) * 2015-02-09 2020-01-30 UCB Biopharma SRL Pharmaceutical formulation
AU2016289480C1 (en) 2015-07-06 2021-10-21 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
RU2731737C2 (ru) 2015-08-19 2020-09-08 Астразенека Аб Стабильный состав на основе антитела к ifnar1
TW201726111A (zh) * 2015-09-30 2017-08-01 持田製藥股份有限公司 含高濃度抗體之液體製劑
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
JP7174699B2 (ja) 2016-11-29 2022-11-17 レゲネロン ファーマシューティカルス，インコーポレーテッド Ｐｒｌｒ陽性乳癌の治療方法
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JPWO2018179138A1 (ja) * 2017-03-29 2020-02-06 持田製薬株式会社 抗体含有液体製剤
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
MA53466A (fr) 2017-04-11 2021-09-08 Kiniksa Pharmaceuticals Ltd Formulation stable d'anticorps anti-osmr
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2019011719A1 (en) 2017-07-10 2019-01-17 Bayer Pharma Aktiengesellschaft PROLACTIN RECEPTOR ANTIBODIES FOR TREATING HAIR LOSS IN MAN AND WOMEN
WO2019099965A1 (en) * 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP3749373A1 (en) 2018-02-07 2020-12-16 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
MX2021002935A (es) * 2018-09-13 2021-06-15 Hoffmann La Roche Formulacion de anticuerpos contra csf-1r.
SG11202103907PA (en) * 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
KR20210084533A (ko) * 2018-10-30 2021-07-07 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨증 (pnh)의 치료를 위한 항-c5 항체의 피하 투여량 및 투여
WO2020172002A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2023230532A1 (en) * 2022-05-26 2023-11-30 Compugen Ltd. Anti-tigit antibody formulation

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JP3919235B2 (ja) 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6525102B1 (en) 1999-10-04 2003-02-25 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
PL224001B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
PT2283856T (pt) 2002-06-21 2017-12-26 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
CN1751236A (zh) * 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
CN1761747A (zh) 2003-03-18 2006-04-19 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
JP2006524195A (ja) 2003-03-18 2006-10-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液状水性医薬組成物
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ES2609010T3 (es) 2003-04-04 2017-04-18 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US7374762B2 (en) 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2004103398A1 (en) 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
DE602004023848D1 (de) 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
WO2005016365A2 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
HUE026793T2 (en) 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd A method for stabilizing an antibody and a stabilized solution-type antibody preparation
DE10361599A1 (de) 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Flüssigformulierung von Antikörperkonjugaten
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004022927A1 (de) 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
DE102005002353A1 (de) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg AGER-Rezeptor Multimerisierungs Epitope
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
EP1893647A2 (en) * 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
EP2377554A1 (en) 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
WO2007095337A2 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
PT2059535E (pt) * 2006-08-18 2014-01-29 Novartis Ag Anticorpos específicos do prlr e suas utulizações
KR20090060453A (ko) 2006-09-25 2009-06-12 메디뮨 엘엘씨 안정화된 항체 제제 및 그것의 용도
KR20090104017A (ko) * 2006-12-11 2009-10-05 에프. 호프만-라 로슈 아게 Ａ베타 항체 비경구 제제
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
US20100143326A1 (en) 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
JP2010524479A (ja) 2007-05-02 2010-07-22 エフ．ホフマン−ラ ロシュ アーゲー タンパク質を安定化する方法
WO2009009406A1 (en) 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
WO2009026122A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
MX2010006395A (es) * 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.
AU2008339984A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2235042A1 (en) 2008-01-23 2010-10-06 Novo Nordisk Health Care AG New blood coagulation factor inhibitors
PE20120169A1 (es) 2008-11-17 2012-02-29 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
NZ613809A (en) * 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
EP2624865B1 (en) * 2010-10-06 2018-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Also Published As

Publication number Publication date
BR112015004397B1 (pt) 2022-07-19
CN111202843A (zh) 2020-05-29
IN2015DN02255A (sr) 2015-08-21
ES2742868T3 (es) 2020-02-17
HUE045494T2 (hu) 2019-12-30
CA2883097C (en) 2022-11-15
TWI641384B (zh) 2018-11-21
ZA201501279B (en) 2016-11-30
IL237277B (en) 2020-04-30
US20150252116A1 (en) 2015-09-10
TW201414491A (zh) 2014-04-16
AR092387A1 (es) 2015-04-22
MX2015002412A (es) 2015-09-29
HRP20191199T1 (hr) 2019-10-18
US8883979B2 (en) 2014-11-11
CN104736175B (zh) 2019-11-01
BR112015004397A2 (pt) 2017-12-19
WO2014036076A1 (en) 2014-03-06
PL2890397T3 (pl) 2019-12-31
DK2890397T3 (da) 2019-08-05
AR092401A1 (es) 2015-04-22
NZ705178A (en) 2018-06-29
KR102100282B1 (ko) 2020-04-13
CY1121990T1 (el) 2020-10-14
IL237277A0 (en) 2015-04-30
US20150093393A1 (en) 2015-04-02
JP6444871B2 (ja) 2018-12-26
AU2013308907A1 (en) 2015-03-12
MX367691B (es) 2019-09-02
UY34999A (es) 2014-03-31
PT2890397T (pt) 2019-09-10
UY34994A (es) 2014-03-31
RU2015111319A (ru) 2016-10-20
LT2890397T (lt) 2019-09-25
KR20150046298A (ko) 2015-04-29
EP2890397B1 (en) 2019-06-19
TWI688404B (zh) 2020-03-21
CA2883097A1 (en) 2014-03-06
EP2890397A1 (en) 2015-07-08
SI2890397T1 (sl) 2019-11-29
RU2649372C2 (ru) 2018-04-02
CN111202844A (zh) 2020-05-29
CN104736175A (zh) 2015-06-24
JP2015528465A (ja) 2015-09-28
TW201821103A (zh) 2018-06-16
AU2013308907B2 (en) 2018-04-19
HK1207316A1 (en) 2016-01-29
US20170008965A1 (en) 2017-01-12
SG11201501225SA (en) 2015-03-30
TW201422235A (zh) 2014-06-16
US20140065158A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
HK1207316A1 (en) Anti-prolactin receptor antibody formulations
HK1203146A1 (en) Antibody formulation
HK1201857A1 (en) Antibody formulations
LT3117837T (lt) Antikūno kompozicijos
IL233592A0 (en) p2x4 receptor antagonist
GB201213700D0 (en) Receptor antagnists II
HK1215175A1 (zh) 抗-催乳素受體抗體製劑
IL244356B (en) Formulations for cgrp receptor antagonists
HK1207985A1 (en) Somatostatin receptor agonist formulations
GB201223053D0 (en) Receptor
HK1210182A1 (en) Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr)
GB201213699D0 (en) Receptor antagonists II
GB201213698D0 (en) Receptor antagonists II